Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biolipox, Orexo deal

ORX will acquire Biolipox for 8.6 million shares valued at SEK776.8 million ($120.9 million) based on ORX's close of SEK90.75 on Oct. 12, the last trading day before

Read the full 287 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE